What low MCHC (and low or high MCH) mean on your blood test

On most reports MCHC sits in the red-cell block, a few lines below hemoglobin and hematocrit, printed in g/dL. MCH is right above it in pg, which stands for picograms. Next to your value is your lab range, and that range is the only one that applies to your result, because it came from the machine that ran your blood. StatPearls says so directly: commonly used reference intervals are provided, but all are lab-specific in practice, and the local laboratory guidelines apply when interpreting a CBC (StatPearls, 2024).

That is not a throwaway caveat here. It is the whole first move. A value flagged low against one lab floor can sit comfortably inside another lab range for the same test, and the searcher who reads a number from a website against a flag from a different lab has compared two different rulers.

While you are looking, write down four numbers together: hemoglobin, MCV, RDW, and MCHC. Those four in that order are what the next several sections work with, and having them in one place saves scrolling back through a portal. You can look up any value on the panel against its typical range while you do it.

This line rarely gets a population number attached to it, so we ran our own. Using the CDC National Health and Nutrition Examination Survey files for August 2021 through August 2023, released in September 2024, we analyzed the complete blood counts of 6,004 US adults aged 18 and over, weighted so the result represents the adult population. All CBCs in that survey were run on a single instrument, a Beckman Coulter DxH 800, which removes the lab-to-lab noise that makes this question hard to answer anywhere else.

In KeptWell's analysis of NHANES 2021 to 2023 data on 6,004 US adults, 2.95 percent had an MCHC below 32 g/dL, and three in four of them also had small red cells, meaning an MCV under 80 fL. The average adult MCHC was 33.76 g/dL, and the middle 95 percent of adults fell between 31.8 and 35.5 g/dL. Below 33 g/dL is not rare at all: 15.79 percent of adults sit there. Above 35 g/dL, 6.52 percent.

Sex matters here. Among women, 4.56 percent were below 32 g/dL, against 1.24 percent of men, which tracks the fact that iron deficiency is far more common in women of reproductive age. MCH ran a mean of 29.81 pg with a middle 95 percent of 23.8 to 34.5 pg, and 8.55 percent of adults were below 27 pg while 12.19 percent were above 32 pg.

That last figure is worth sitting with, because it collides with what people read. One widely read consumer health site calls an MCH above 31 pg high. Cleveland Clinic prints 27 to 31 pg on its complete blood count page and 27 to 33 pg on its own MCH page. StatPearls says 27 to 32 pg.

So a person with an MCH of 32.5 is high by one source, normal by another, and in the company of roughly one in eight US adults by our own count. The same disagreement runs through MCHC: UCSF and Cleveland Clinic both publish 32 to 36 g/dL, while a hospital lab reference table reproduced in a 2018 case report prints 32.0 to 34.5 g/dL. An MCHC of 35 is unremarkable at one lab and flagged high at the other.

None of this means the ranges are wrong. It means low and high are lab-relative statements, which is exactly what the parent guide on reading lab results says about flags in general. Our numbers are point estimates from a single survey cycle on a single analyzer, without confidence intervals, so read them as a map of where people sit rather than as a new reference range.

Doctors do not read a CBC top to bottom, and neither should you. There is an order, and it rarely gets written down. Start with hemoglobin, because it answers the only question that changes what happens next: is there anemia at all? If hemoglobin is normal, everything below it on the red-cell block is describing the character of cells that are doing their job.

MCV comes second, because size sorts the causes into three buckets. StatPearls puts normal at 80 to 100 fL, with under 80 called microcytic and over 100 macrocytic. Small cells point toward iron and thalassemia trait. Large cells point toward B12, folate, alcohol, thyroid and liver. Normal-sized cells point toward blood loss, inflammation and everything else.

RDW comes third. It measures how much your cell sizes vary, and it is the line that separates iron deficiency from thalassemia trait when both are producing small cells. In iron deficiency the marrow starts shipping small cells while normal ones are still circulating, so variation rises; thalassemia trait produces more uniform microcytosis, often with a normal RDW (StatPearls, 2026). If your RDW is flagged too, the companion guide on a high RDW covers that line on its own.

MCH and MCHC come last, and they mostly restate what MCV and RDW already said. StatPearls is blunt about the redundancy: MCH is dependent on cell volume and correlates closely with MCV, while MCHC indicates hemoglobin density controlling for MCV. Reading MCHC before hemoglobin is how a normal blood count turns into a bad night.

Low MCHC has a formal name, hypochromia, and StatPearls gives its causes in one sentence: hypochromic anemia may be due to decreased hemoglobin production, most commonly iron deficiency, less commonly copper deficiency, pyridoxine (vitamin B6) deficiency or lead poisoning, or due to reticulocytosis, since reticulocytes carry less hemoglobin than mature red cells. A marrow busy replacing cells, including a marrow responding to iron treatment, can push MCHC down. Recovery can look like the problem.

Iron deficiency is the front-runner by a wide margin, and it is not rare. A 2024 study in JAMA Network Open using national survey data found absolute iron deficiency in 14 percent of US adults, in 34 percent of women aged 18 to 50, and in 11 percent of adults who had no anemia, heart failure, kidney disease or pregnancy. That last figure describes exactly the person searching this phrase: iron stores running low while hemoglobin still reads normal.

Our own numbers say the same thing from the other direction. Among US adults with an MCHC below 32 g/dL, 75 percent had an MCV under 80 fL and 80 percent had an RDW above 15 percent. In other words, a low MCHC usually travels in a group, and the group is the iron picture. Only roughly one in six of them had both a normal hemoglobin and a normal MCV, and that subgroup is small enough in the survey (about 30 people) that it is a rough proportion rather than a precise one.

The look-alikes matter. Thalassemia trait produces small, hemoglobin-poor cells for life, with a normal RDW and normal iron studies, and it needs no treatment; iron given for it accumulates instead of helping. Anemia of inflammation, the pattern seen with rheumatoid arthritis, inflammatory bowel disease, chronic infection and kidney disease, works by locking iron away from red cell production rather than by running out of it, so ferritin reads normal or high while the cells still come out underfilled. Copper deficiency, B6 deficiency, lead exposure and sideroblastic anemia round out the list, and all four are uncommon enough that they are looked for after ferritin comes back.

One honest limit on all of this: the indices are the insensitive end of the test. Up to 40 percent of people with iron-deficiency anemia have normal-sized red cells (American Family Physician, 2013), and a 2008 review in the American Journal of Medicine notes that MCV stays inside the normal range until hemoglobin has already fallen to roughly 10 g/dL. Normal indices do not rule iron deficiency out. Ferritin does.

A high MCH means each red cell carries more hemoglobin than usual, and the usual reason is simply that the cells are bigger. Because MCH is hemoglobin divided by red cell count, anything that enlarges cells raises it. That is why high MCH and high MCV almost always appear together, and why the causes list for one is the causes list for the other.

StatPearls defines macrocytosis as an MCV above 100 fL and sorts the causes into two groups. The megaloblastic group is B12 deficiency, folate deficiency, and drugs that interfere with DNA synthesis, including methotrexate, trimethoprim-sulfamethoxazole, hydroxyurea, phenytoin, pyrimethamine, sulfasalazine and triamterene. The non-megaloblastic group is alcohol, hypothyroidism, liver disease, and marked reticulocytosis from states of rapid red cell turnover such as hemolysis. HIV medicines, particularly zidovudine, stavudine and lamivudine, do the same (StatPearls, 2025).

Two entries on that list are worth naming for a family reading a parent record. Alcohol raises MCV and MCH without any vitamin deficiency at all, and it is one of the most common explanations in adults. Thyroid disease does the same and is checked with a single blood test.

The honest overlap is this: because MCH tracks MCV so closely, a high MCH with a normal MCV is usually a borderline calculation rather than a separate finding, and the workup is driven by the MCV and the hemoglobin. If both are up, the standard next tests are B12, folate, a thyroid panel and liver enzymes, plus an honest conversation about alcohol.

This is the section the search results get wrong, and the correction is straightforward. StatPearls says it plainly: increased MCHC can be caused by red cell shape abnormalities such as spherocytosis and xerocytosis, or by hemoglobinopathies, but more commonly, high MCHC represents an artifact. The listed artifacts are lipemia (fat in the sample, which falsely raises the measured hemoglobin), hemolysis (cells broken during or after the draw), red cell agglutination (cells clumping, which falsely lowers the count), a very high white cell count, and a high bilirubin.

The mechanism follows straight from the formula. MCHC is hemoglobin divided by hematocrit, so anything that falsely raises the hemoglobin or falsely lowers the hematocrit inflates the ratio, without a single thing being wrong with your red cells. Cold agglutinins are the classic version: certain antibodies make cells clump in a cool tube, and a published case report describes exactly that, with cold agglutinins causing artificially decreased red cell counts and increased MCV and MCHC (Biochemia Medica, 2014). Warming the sample and running it again fixes it.

Labs know this and use it. A 2018 case report puts the lab view in one sentence: MCHC is one of the most indicative parameters generated by hematology analyzers because of the way it is calculated, and its abnormalities alarm the user that the sample has to be checked. In the same paper, a high MCHC is described as a good indicator of analysis or sample error. Your high MCHC may be doing its job, which is telling the lab that the tube was wrong.

There is also a ceiling. StatPearls notes that a red cell hemoglobin content is regulated and normally limited to a density of roughly 34 percent hemoglobin per cell, which is why very high values are uncommon in biology and common in bad samples. In KeptWell's analysis of national survey data, 6.52 percent of US adults were above 35 g/dL and 0.51 percent were above 36 g/dL, the latter resting on only 28 respondents, so read it as approximate.

When a high MCHC is real, the causes are hereditary spherocytosis, xerocytosis and some hemoglobin disorders, and the next step is not a specialist referral. StatPearls says an examination of a peripheral blood smear is essential in assessing any abnormal CBC result and is recommended, and a smear is what shows the cell shapes and rules out the interferences above. A smear and a repeat draw settle most of these.

Type this search and the suggestions fill in with cancer, so here is the honest structure of the answer. No guideline treats MCHC or MCH as a cancer test. Every guideline pathway that leads toward a cancer workup starts somewhere else: at iron-deficiency anemia, meaning a low hemoglobin together with a low ferritin. The index is a description of your red cells. The anemia is what gets investigated.

That pathway is real and it is worth knowing, because it is the one situation where this family of numbers connects to something serious. The American Gastroenterological Association 2020 guideline recommends using a ferritin cutoff of 45 ng/mL over 15 ng/mL to diagnose iron deficiency in patients with anemia, which it grades a strong recommendation on high-quality evidence. It then recommends bidirectional endoscopy, meaning both an upper endoscopy and a colonoscopy, over no endoscopy in asymptomatic postmenopausal women and men with iron-deficiency anemia, a strong recommendation on moderate-quality evidence. For asymptomatic premenopausal women it suggests bidirectional endoscopy over iron replacement alone, a conditional recommendation.

The reason for that escalation is a number, and American Family Physician published it in its 2021 summary of the guideline: among men and postmenopausal women evaluated for iron-deficiency anemia, colonic malignancy is found in 9 percent and upper gastrointestinal malignancy in 2 percent. Among premenopausal women, malignancy is diagnosed in 1 percent. The guideline also suggests testing for Helicobacter pylori when endoscopy finds nothing, and serologic testing for celiac disease before any small-bowel biopsy.

Read that carefully, because it is both more serious and more specific than the vague warnings on most pages. Unexplained iron loss in an adult who should not be losing iron deserves a look at the gut. A low MCHC with a normal hemoglobin and a normal ferritin is not that situation, and no guideline sends it anywhere.

The follow-up for a low MCHC or MCH is a short list of ordinary blood tests, not imaging. StatPearls lists the standard workup for a hypochromic microcytic picture: a CBC with indices, an iron panel covering TIBC, transferrin saturation and ferritin, a peripheral smear, hemoglobin electrophoresis if a thalassemia is possible, and lead or specialized testing in the uncommon cases. If the cells are large instead, the list is B12, folate, thyroid and liver tests.

Note that the sources disagree on the ferritin cutoff, and saying so is more useful than pretending they do not. AGA sets it at 45 ng/mL in anemic patients. The Merck Manual calls levels under 30 ng/mL specific for iron deficiency. American Family Physician discusses both 15 and 30. Your doctor is choosing among current, reputable numbers, which is part of why a borderline ferritin gets a conversation rather than an automatic prescription.

Timing surprises people, so here it is in order. On iron treatment, reticulocytes rise first, within three to seven days, and hemoglobin follows in two to four weeks (American Journal of Medicine, 2008). American Family Physician treats a rise of 1 g/dL after one month as confirmation that the diagnosis was right. Merck expects the anemia corrected within two months and recommends continuing iron for at least six months after that to refill stores, while American Family Physician says three months. The indices are last, because red cells live about 120 days and the average cannot move until most of the underfilled cells have been replaced. Your MCHC is the slowest number on the report.

One thing not to do while you wait: do not start iron for a low MCHC without a ferritin. If the cause is thalassemia trait, iron will not raise the number and will accumulate. If the cause is a sample artifact, there is nothing to raise. And if the cause is slow bleeding, iron can normalize the count while leaving the source unfound, which is the exact scenario the 9 percent figure in the previous section depends on catching.

This is where your own records do more than any search. A 31.6 that has read 31-and-something on every CBC for six years has already answered the frightening version of the question. A 31.6 that was 34.2 last spring is worth the ferritin even though both look similar on one page. That is the method in reading your test results before your doctor calls: whole panel first, then flags, then today next to last time.

Most write-ups end at talk to your provider without saying what to say. Here is the script, in the order that gets you a useful answer in a short visit. Start with the framing question: is my hemoglobin normal, and if it is, does this index change anything? Then: has my ferritin been checked, and what was it? Then: has this value changed from my previous CBCs, or has it always been here?

If the answer points toward iron, three more: do we know why I am losing or not absorbing iron, should I be on iron, and when do we recheck? If the answer points toward large cells, ask about B12, folate, thyroid and any medicine on the list. And if the MCHC is the high one, one question does most of the work: could this be the sample, and should it be redrawn?

Bring the previous reports, not just the latest one. The trend answers questions the single value cannot, and it is the fastest way to turn a flagged index into a settled one.

This is the part KeptWell was built for. Upload the lab report and it is read and explained: the flagged line decoded in plain English, the source line shown, never a diagnosis. Because your CBCs live in one organized place, the question that settles this line, what has this number been before, has an answer in seconds instead of a hunt through three portals. And if you are watching these numbers for an aging parent, the whole family sees the same report and the same explanation, which spares each of you a separate late-night search over the same two decimals.